Achillion Pharmaceuticals (ACHN) 7.53 -0.06

Achillion Pharmaceuticals, Inc.
(ACHN) 7.53 -0.06

Last Trade:	7.51	Day Range:	7.38 - 7.57
Trade Time:	05:05PM	52wk Range:	3.81 - 12.95
Prev. Close:	7.57	Market Cap:	530.55M
Open:	7.46	Div Yield:	0
Volume:	630695	PE:
EPS:	-0.65

The Latest On ACHN

A Peek Into The Market Before The Trading Starts 5/15/12 7:33am

ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C 5/15/12 7:02am

UPDATE: UBS Investment Research Upgrades Achillion to Neutral; Balanced Risk/Reward 5/7/12 12:55pm

Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C 4/23/12 9:26am

Benzinga's Top Pre-Market Losers 4/23/12 8:18am

Benzinga's Top Downgrades 4/23/12 7:56am

Notable Options Activity in Achillion Pharmaceuticals, Inc. 4/19/12 11:36am

Benzinga's Top Pre-Market Losers 4/19/12 8:11am

UPDATE: Bank of America Raises Actuant's PT 3/8/12 2:02pm

Piper Jaffray: Achillion Pharmaceuticals Ended 2011 with $80M Cash 3/8/12 1:50pm

Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish 2/17/12 1:30pm

Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix 2/17/12 8:54am

A Peek Into The Market Before The Trading Starts 5/15/12

ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C 5/15/12

UPDATE: UBS Investment Research Upgrades Achillion to Neutral; Balanced Risk/Reward 5/7/12

Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C 4/23/12

Benzinga's Top Pre-Market Losers 4/23/12

Benzinga's Top Downgrades 4/23/12

Notable Options Activity in Achillion Pharmaceuticals, Inc. 4/19/12

Benzinga's Top Pre-Market Losers 4/19/12

UPDATE: Bank of America Raises Actuant's PT 3/8/12

Piper Jaffray: Achillion Pharmaceuticals Ended 2011 with $80M Cash 3/8/12

Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish 2/17/12

Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix 2/17/12

Notable Options Activity in Achillion Pharmaceuticals, Inc. 4/19/12

Benzinga's M&A Chatter for Wednesday February 8, 2012 2/8/12

Financial Breakfast: Morning News Summary for February 07, 2012 2/7/12

Benzinga's M&A Chatter for Thursday February 2, 2012 2/2/12

Benzinga's M&A Chatter for Tuesday January 24, 2012 1/24/12

Benzinga's M&A Chatter for Friday January 20, 2012 1/20/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Forget Dendreon, Inhibitex is the New Biotech Success Story 1/9/12

Best Biotech Stocks of 2011 12/27/11

Hep-C Stocks Soar On M&A News 11/21/11

Biotech Leads Friday's NASDAQ Winners 10/17/11

UPDATE: UBS Investment Research Upgrades Achillion to Neutral; Balanced Risk/Reward 5/7/12

Benzinga's Top Downgrades 4/23/12

UPDATE: Bank of America Raises Actuant's PT 3/8/12

Piper Jaffray: Achillion Pharmaceuticals Ended 2011 with $80M Cash 3/8/12

Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish 2/17/12

Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix 2/17/12

Financial Breakfast: Morning News Summary for February 07, 2012 2/7/12

UPDATE: Bank of America Downgrades Achillion Pharmaceuticals to Underperform 2/7/12

Bank of America Downgrades Achillion Pharmaceuticals from Buy to Underperform, Lowers PO from $11 to $10 2/7/12

End-of-Day Market Summary for January 20, 2012 1/20/12

End-of-Day Market Summary for January 10, 2012 1/10/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Trade ACHN
NOW!

Partner Headlines

Up/Downgrades 5/7/12

Grading Hep C Stocks Exiting EASL Confab 4/23/12

Health Care Sector Wrap 4/19/12

New Ratings from Analysts 4/12/12

For Biotech, 'Fail' is Making a Big Comeback 3/12/12

8 Stocks Rising on Monster Volume 2/17/12

Hedge Funds Catch Hep C Fever 2/15/12

Biotech Stock Mailbag: Vical, Hep C Drugs 1/27/12

Company News for January 25, 2012 - Corporate Summary 1/25/12

BioLineRx: Tuesday's Hot Hep C Drug Stock 1/24/12

Press Releases

Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis C 5/21/12 GlobeNewswire

Achillion Announces Executive Promotion 5/18/12 GlobeNewswire

ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C 5/15/12 GlobeNewswire

Achillion Reports First Quarter 2012 Financial Results 5/9/12 GlobeNewswire

Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development 5/9/12 GlobeNewswire

Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C 4/23/12 GlobeNewswire

Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C 4/21/12 GlobeNewswire

Achillion Reports 2011 Fourth Quarter and Year-End Financial Results 3/8/12 GlobeNewswire

Achillion Fourth Quarter and Full Year 2011 Financial Release and Conference Call Alert 3/2/12 GlobeNewswire

Achillion to Present at Two Upcoming Investor Conferences 3/1/12 GlobeNewswire

AMRS, KWK, ACHN, DNDN, and JAZZ Could See Big Gains, Reports Thestockfather.com 2/25/12 Emailwire

Virology Profile Following Treatment With ACH-1625 Discussed in Oral Presentation at 2012 Asian Pacific Liver Conference 2/16/12 GlobeNewswire

Get the latest ACHN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Achillion Pharmaceuticals, Inc. stock price.

Achillion Pharmaceuticals, Inc. by YCharts

Achillion Pharmaceuticals (ACHN) 7.53 -0.06

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On ACHN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social